

Elisabeth Rexen Ulven

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7776305/publications.pdf>

Version: 2024-02-01

34
papers

1,744
citations

304368

22
h-index

377514

34
g-index

37
all docs

37
docs citations

37
times ranked

1946
citing authors

#	ARTICLE	IF	CITATIONS
1	The Pharmacology of TUG-891, a Potent and Selective Agonist of the Free Fatty Acid Receptor 4 (FFA4/GPR120), Demonstrates Both Potential Opportunity and Possible Challenges to Therapeutic Agonism. <i>Molecular Pharmacology</i> , 2013, 84, 710-725.	1.0	172
2	Discovery of Potent and Selective Agonists for the Free Fatty Acid Receptor 1 (FFA1/GPR40), a Potential Target for the Treatment of Type II Diabetes. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7061-7064.	2.9	127
3	Polyunsaturated fatty acid receptors, GPR40 and GPR120, are expressed in the hypothalamus and control energy homeostasis and inflammation. <i>Journal of Neuroinflammation</i> , 2017, 14, 91.	3.1	104
4	Selective Orthosteric Free Fatty Acid Receptor 2 (FFA2) Agonists. <i>Journal of Biological Chemistry</i> , 2011, 286, 10628-10640.	1.6	101
5	Defining the Molecular Basis for the First Potent and Selective Orthosteric Agonists of the FFA2 Free Fatty Acid Receptor. <i>Journal of Biological Chemistry</i> , 2013, 288, 17296-17312.	1.6	99
6	Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. <i>British Journal of Nutrition</i> , 2015, 113, 1677-1688.	1.2	93
7	Dietary Fatty Acids and Their Potential for Controlling Metabolic Diseases Through Activation of FFA4/GPR120. <i>Annual Review of Nutrition</i> , 2015, 35, 239-263.	4.3	87
8	Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8868-8878.	2.9	81
9	Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. <i>FASEB Journal</i> , 2012, 26, 4951-4965.	0.2	75
10	A protocol for amide bond formation with electron deficient amines and sterically hindered substrates. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 430-433.	1.5	72
11	Identification of a Potent and Selective Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist with Favorable Physicochemical and in Vitro ADME Properties. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6691-6703.	2.9	65
12	Reevaluation of Fatty Acid Receptor 1 as a Drug Target for the Stimulation of Insulin Secretion in Humans. <i>Diabetes</i> , 2013, 62, 2106-2111.	0.3	64
13	Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 441-445.	1.3	58
14	Complex Pharmacology of Novel Allosteric Free Fatty Acid 3 Receptor Ligands. <i>Molecular Pharmacology</i> , 2014, 86, 200-210.	1.0	58
15	Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 345-349.	1.3	56
16	Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 982-992.	2.9	52
17	Conjugated Linoleic Acids Mediate Insulin Release through Islet G Protein-coupled Receptor FFA1/GPR40. <i>Journal of Biological Chemistry</i> , 2011, 286, 11890-11894.	1.6	51
18	Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonists: Methylpropoxy Appendage Lowers Lipophilicity and Improves ADME Properties. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6624-6628.	2.9	50

#	ARTICLE	IF	CITATIONS
19	Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4849-4858.	2.9	40
20	Receptor structure-based discovery of non-metabolite agonists for the succinate receptor GPR91. <i>Molecular Metabolism</i> , 2017, 6, 1585-1596.	3.0	40
21	Development and Characterization of a Fluorescent Tracer for the Free Fatty Acid Receptor 2 (FFA2/GPR43). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5638-5645.	2.9	32
22	Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9534-9550.	2.9	29
23	Chemogenetics defines a short-chain fatty acid receptor gut-brain axis. <i>ELife</i> , 2022, 11, .	2.8	21
24	Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2841-2846.	2.9	20
25	FFA2-, but not FFA3-agonists inhibit GSIS of human pseudoislets: a comparative study with mouse islets and rat INS-1E cells. <i>Scientific Reports</i> , 2020, 10, 16497.	1.6	17
26	A Rapid and Efficient Sonogashira Protocol and Improved Synthesis of Free Fatty Acid 1 (FFA1) Receptor Agonists. <i>Journal of Organic Chemistry</i> , 2010, 75, 1301-1304.	1.7	16
27	In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 1021-1030.	1.4	12
28	Structure-Activity Investigations and Optimisations of Non-metabolite Agonists for the Succinate Receptor 1. <i>Scientific Reports</i> , 2018, 8, 10010.	1.6	11
29	Structure-based discovery of novel US28 small molecule ligands with different modes of action. <i>Chemical Biology and Drug Design</i> , 2017, 89, 289-296.	1.5	10
30	Structure-Activity Relationship Studies of Tetrahydroquinolone Free Fatty Acid Receptor 3 Modulators. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3577-3595.	2.9	8
31	Mucus can change the permeation rank order of drug candidates. <i>International Journal of Pharmaceutics</i> , 2013, 452, 276-282.	2.6	7
32	Dihydropyridine Fluorophores Allow for Specific Detection of Human Antibodies in Serum. <i>ACS Omega</i> , 2018, 3, 7580-7586.	1.6	6
33	Acute effects of delayed-release hydrolyzed pine nut oil on glucose tolerance, incretins, ghrelin and appetite in healthy humans. <i>Clinical Nutrition</i> , 2021, 40, 2169-2179.	2.3	5
34	Structure-Activity Relationship Explorations and Discovery of a Potent Antagonist for the Free Fatty Acid Receptor 2. <i>ChemMedChem</i> , 2021, 16, 3326-3341.	1.6	2